City

Boston (1)

Chicago (1)

Rochester (1)

Overall Status

Completed (2)

Withdrawn (1)

Phase

n/a (1)

phase 1 (1)

phase 2 (1)

Sponsor

Mayo Clinic (1)

National Cancer Institute (NCI) (1)

Ohio State University Comprehensive Cancer Center (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

laboratory biomarker analysis (2)

computed tomography (1)

oncolytic measles virus encoding thyroidal sodium iodide symporter (1)

photodynamic therapy (1)

porfimer sodium (1)

single photon emission computed tomography (1)

sorafenib tosylate (1)

therapeutic conventional surgery (1)

Study Documents

Intervention Type

drug (2)

other (2)

procedure (2)

biological (1)

Funder Type

Other (2)

NIH (1)

Study Type

Interventional (3)

stage iii malignant mesothelioma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Recurrent Malignant Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma Trial in Rochester

Completed

Recurrent Malignant Mesothelioma
+5 more

oncolytic measles virus encoding thyroidal sodium iodide symporter
+3 more

Rochester, Minnesota

Mayo Clinic

Jan 8, 2021

Stage III Malignant Mesothelioma, Stage IIIB NSCLC, Stage IV Malignant Mesothelioma Trial (porfimer sodium, therapeutic

Withdrawn

Stage III Malignant Mesothelioma
+3 more

porfimer sodium
+2 more

(no location specified)

Mar 19, 2019

Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma Trial in Chicago, Boston (sorafenib

Completed

Epithelial Mesothelioma
+7 more

sorafenib tosylate
laboratory biomarker analysis

Chicago, Illinois
+1 more

Jun 4, 2013